A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma
Status:
NOT_YET_RECRUITING
Trial end date:
2030-01-19
Target enrollment:
Participant gender:
Summary
The study will consist of a Phase I dose-escalation and Phase IIa dose-expansion component. Phase I dose-escalation phase will establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D),and evaluate the preliminary antitumor activity of HX111.